Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-03-12
Disclosure Type: Single Sales/Supply Contract
💡 3-Second Summary
Samsung Biologics has signed a new biopharmaceutical contract manufacturing organization (CMO) contract valued at approximately KRW 92.8 billion with a subsidiary of global pharmaceutical giant Merck (Merck Sharp & Dohme (Switzerland) GmbH), establishing a long-term revenue pipeline running through 2032.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Counterparty: Merck Sharp & Dohme (Switzerland) GmbH (Subsidiary of Merck)
- Contract Type: Biopharmaceutical Contract Manufacturing Organization (CMO) Contract
- Contract Amount: KRW 92,769,116,464 (Approx. KRW 92.8B)
- This figure was calculated by applying the initial exchange rate of 1,314.40 KRW/USD on the contract date (March 12, 2024) to the fixed contract amount of USD 70,579,060.
- Proportion to Annual Revenue: 3.09%
- The baseline annual revenue (KRW 3,001,295,197,683) is based on the company’s 2022 consolidated financial statements.
- Contract Period: March 1, 2024 – December 31, 2032 (An approximate 8-year long-term agreement).
- Other Details: The contract end date is subject to change upon mutual agreement between both parties. This filing was made without any regulatory non-disclosure options, immediately identifying the counterparty.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
- Impact on Fundamental Changes: This filing announces a newly secured revenue stream. While the contract value of approximately KRW 92.8 billion (3.09% of baseline revenue) is not large enough to catalyze short-term earnings spikes, locking in a fixed commercial pipeline through late 2032 strengthens long-term structural revenue stability, creating a positive potential impact.
- Risks and Red Flags for Investors: The regulatory disclosure does not specify the explicit operational details, such as the targeted clinical/commercial product lines or detailed volume breakdowns, meaning market participants should avoid ungrounded conclusions. Additionally, because the monetary total remains tied to the historical exchange rate from March 12, 2024 (1,314.40 KRW/USD), actual recognized revenue could fluctuate depending on spot exchange rates during active billing cycles. Furthermore, as the contract termination date remains subject to change based on mutual agreement, the long-term execution timeline may remain fluid.
📝 Editor’s Comment (by K-STOCK Editor)
A formal filing has been submitted for a new CMO procurement order from Merck’s Swiss entity. While the contract size represents a modest 3.09% of baseline annual revenue and is unlikely to spark immediate aggressive price volatility, the absence of any non-disclosure options regarding the client’s identity underscores the immediate transparency and binding finality of the transaction. This addition steadily builds into the company’s long-term backlog expanding through 2032. Institutional researchers will likely maintain a balanced approach, tracking whether this structural layout leads to subsequent upward volume adjustments or broader procurement expansions in future quarters.
📢 Disclaimer and Source Information
Source: This content has been structured and newly written based on official submission data from the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
